These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36171843)

  • 1. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
    Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
    Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
    Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
    J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
    Paepegaey AC; Lheure C; Ratour C; Lethielleux G; Clerc J; Bertherat J; Kramkimel N; Groussin L
    J Endocr Soc; 2017 Jun; 1(6):646-649. PubMed ID: 29264517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review.
    Hinata Y; Ohara N; Sakurai Y; Koda R; Yoneoka Y; Takada T; Hara N; Nishiyama T
    Am J Case Rep; 2021 Jul; 22():e931639. PubMed ID: 34262010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.
    Spagnolo CC; Campo I; Campennì A; Cardile D; Cannavò S; Silvestris N; Santarpia M; Ruggeri RM
    Hormones (Athens); 2024 Dec; 23(4):759-764. PubMed ID: 38421588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab in the management of metastatic melanoma.
    Spain L; Younger E; Hatipoglu E; Larkin J
    Melanoma Manag; 2015 Nov; 2(4):315-325. PubMed ID: 30190860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
    Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
    Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.
    He X; Tu R; Zeng S; He Z; Liu S; Fang Y
    Curr Probl Cancer; 2022 Aug; 46(4):100863. PubMed ID: 35687965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency.
    Hanna RM; Selamet U; Bui P; Sun SF; Shenouda O; Nobakht N; Barsoum M; Arman F; Rastogi A
    Case Rep Nephrol Dial; 2018; 8(2):171-177. PubMed ID: 30197906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.
    Cui K; Wang Z; Zhang Q; Zhang X
    Ann Transl Med; 2022 Mar; 10(5):251. PubMed ID: 35402601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody).
    Jagpal A; Choudhary G; Chokr J
    Proc (Bayl Univ Med Cent); 2019 Jul; 32(3):419-421. PubMed ID: 31384207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.